FDA Approves CartiHeal, Bioventus Buys Company For $315mm
On March 30, 2022, Israel-based CartiHeal Ltd, announced FDA PMA (premarket approval) for its Agili-C implant for treating knee joint surface lesions. Five days later, April 4, Durham, Bioventus announced plans to buy CartiHeal for about $315 million.














































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































